Cirqle Biomedical, of Copenhagen, said it secured $1.8 million for preclinical development of a non-hormonal contraceptive technology that leverages the natural barrier properties of cervical mucus. It has developed a topically-applied biopolymer that makes cervical mucus impenetrable to sperm cells throughout a woman's cycle.